Home » Posts tagged with » pharma acquisition news
Sanofi to acquire UK-based biopharma company Kymab in $1.4bn worth deal

Sanofi to acquire UK-based biopharma company Kymab in $1.4bn worth deal

Sanofi acquisition of Kymab : French pharma giant Sanofi has signed a deal worth up to $1.45 billion to acquire Kymab, a UK-based clinical-stage biopharma company focused on developing fully human monoclonal antibodies, particularly for immune-mediated diseases, and immuno-oncology therapeutics. The consideration includes an upfront payment of around $1.1 billion and up to $350 million […]

Novartis to acquire neuroscience company Cadent Therapeutics in $770m worth deal

Novartis acquisition of Cadent Therapeutics : Swiss pharma giant Novartis has agreed to acquire a US neuroscience company Cadent Therapeutics, in a deal worth up to $770 million. The consideration includes an upfront payment of $210 million and up to $560 million in milestone payments. Cadent Therapeutics was launched about three years ago via the […]

Continue reading …
Lilly to acquire US gene therapy company Prevail Therapeutics in $1bn deal

Eli Lilly and Company (Lilly) has signed a deal worth up to $1.04 billion to acquire Prevail Therapeutics, a US gene therapy company engaged in developing disease-modifying AAV9-based gene therapies for neurodegenerative diseases. According to the US pharma giant, the acquisition will set up a new modality for drug discovery and development. It will also […]

Continue reading …
EQT offers to acquire Swedish CDMO Recipharm for $2.8bn

Swedish private equity company EQT Partners has offered to takeover Recipharm, a Swedish pharma contract development and manufacturing organization (CDMO), for SEK 23.6 billion ($2.82 billion). As per the terms of the offer, Recipharm’s shareholders are being offered SEK 220 ($26.3) in cash for each of its class B shares EQT IX, a fund managed […]

Continue reading …
AstraZeneca to acquire US biopharma company Alexion Pharmaceuticals for $39bn

AstraZeneca acquisition of Alexion Pharmaceuticals : Pharma giant AstraZeneca has signed a $39 billion deal to acquire Alexion Pharmaceuticals, a US biopharma company engaged in developing therapies for rare disorders. As per the terms of the deal, Alexion Pharmaceuticals’ shareholders will be paid $60 in cash and 2.1243 American Depositary Shares (ADSs) of AstraZeneca, valuing […]

Continue reading …
Gilead Sciences to acquire HDV drug developer MYR in €1.4bn deal

Gilead Sciences acquisition of MYR : US biopharma giant Gilead Sciences has agreed to acquire MYR, a German biotech company engaged in developing therapies for chronic hepatitis delta virus (HDV), in a deal worth up to €1.45 billion. The consideration consists of nearly €1.15 billion in cash, which will be paid at the time of […]

Continue reading …
Boehringer Ingelheim to acquire NBE-Therapeutics for €1.1bn

German pharma company Boehringer Ingelheim has signed a deal worth €1.18 billion to acquire NBE-Therapeutics, a clinical-stage Switzerland-based biotech company, focused on developing antibody-drug conjugates (ADCs) and advancing targeted cancer therapies. Through the acquisition, Boehringer Ingelheim will gain access to the Swiss firm’s iADC platform, which is capable of creating immune stimulatory ADCs with an […]

Continue reading …
Merck to acquire OncoImmune for Covid-19 drug candidate CD24Fc

Merck acquisition of OncoImmune : Pharma giant Merck has signed an all-cash deal worth $425 million to acquire OncoImmune to gain access to the latter’s investigational Covid-19 drug – CD24Fc. Based in Maryland, OncoImmune is a clinical-stage biopharma company, that is focused on the discovery and development of therapies for cancer and autoimmune disease. As […]

Continue reading …
Bristol Myers Squibb wraps up $13.1bn acquisition of MyoKardia

Bristol Myers Squibb has wrapped up its previously announced $13.1 billion acquisition of MyoKardia, a California-based clinical-stage biopharma company. Following the closing of the deal, the shares of MyoKardia have ceased trading on the NASDAQ Global Select Market and the company is now a fully-owned subsidiary of Bristol Myers Squibb. As per the terms of […]

Continue reading …
Merck to acquire US biopharma company VelosBio to strengthen oncology pipeline

Merck acquisition of VelosBio : US pharma giant Merck has agreed to acquire VelosBio, a California-based clinical-stage biopharma company, for $2.75 billion in an all-cash deal, in a move to strengthen its oncology pipeline. VelosBio is engaged in developing cancer therapies that target receptor tyrosine kinase-like orphan receptor 1 (ROR1). The company’s lead investigational candidate […]

Continue reading …
Page 1 of 9123Next ›Last »